Fujifilm building a plant in Japan to produce liposomes

Fujifilm will invest about $37.5 million to build a facility to make liposomes that it intends to use in its FF-10832 and other cancer drug candidates. Lipsomes serve as a nano-delivery vehicle. (Wikimedia Commons)

Japan’s Fujifilm, whose pharma division is moving toward clinical trials for a cancer drug, is building a plant to produce liposomes that can be the delivery vehicles for it and other drug candidates.

The company said last week that it will invest about 4 billion yen ($37.5 million) to build the plant at the production site of its Toyama Chemical unit in Tokyo. It said construction is slated to begin in September and to be operational by February 2020.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The Japanese company said it intends to use advanced nano-dispersion technology, analysis technology and process technology cultivated through its photographic film business for the development of liposome drugs that will efficiently deliver the active ingredient to the affected area and enhance efficacy.

Fujifilm hopes to start clinical trials this year on its anticancer drug candidate FF-10832 but said the new plant will also be used to develop other liposome drugs.

RELATED: Fuji completes cell culture manufacturing expansion in U.K.

Separately, Fujifilm’s contract manufacturing operations has been expanding with about $130 million in announced investments in its 10,000-square-foot, cell culture process development laboratories in Billingham, U.K.

The additional funding will support its monoclonal antibody platform for cell culture development work, as well as its cell culture facility in Texas.

Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.

The FDA hit United Exchange Corp. with a warning letter, citing the company for a number of “significant” violations with its quality-control systems.